HUMACYTE INC. - COMMON STOCK

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

26 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

22 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

01 Mar 2024 08:16:19 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

29 Feb 2024 20:18:05 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

29 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

09 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

24 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

17 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Third Quarter 2023 Financial Results and Business Update

09 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

02 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

16 Oct 2023 07:55:42 By Nasdaq GlobeNewswire

Humacyte to Present at the Cantor Global Healthcare Conference

21 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

18 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

12 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET

11 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program

15 Aug 2023 07:00:00 By Nasdaq GlobeNewswire